| Response . | Pemetrexed/carboplatin + apatorsen (n = 77), n (%) . | Pemetrexed/carboplatin + placebo (n = 78), n (%) . | All patients (n = 155), n (%) . |
|---|---|---|---|
| Objective response rate | 21 (27) | 25 (32) | 46 (30) |
| Complete response | 1 (1) | 0 (0) | 1 (1) |
| Partial response | 20 (26) | 25 (32) | 45 (29) |
| Stable disease | 31 (40) | 38 (49) | 69 (45) |
| ≥6 months | 9 (12) | 6 (8) | 15 (10) |
| <6 months | 22 (29) | 32 (41) | 54 (35) |
| Progressive disease | 10 (13) | 6 (8) | 16 (10) |
| Not evaluable | 15 (20) | 9 (12) | 24 (16) |
| Response . | Pemetrexed/carboplatin + apatorsen (n = 77), n (%) . | Pemetrexed/carboplatin + placebo (n = 78), n (%) . | All patients (n = 155), n (%) . |
|---|---|---|---|
| Objective response rate | 21 (27) | 25 (32) | 46 (30) |
| Complete response | 1 (1) | 0 (0) | 1 (1) |
| Partial response | 20 (26) | 25 (32) | 45 (29) |
| Stable disease | 31 (40) | 38 (49) | 69 (45) |
| ≥6 months | 9 (12) | 6 (8) | 15 (10) |
| <6 months | 22 (29) | 32 (41) | 54 (35) |
| Progressive disease | 10 (13) | 6 (8) | 16 (10) |
| Not evaluable | 15 (20) | 9 (12) | 24 (16) |
| Response . | Pemetrexed/carboplatin + apatorsen (n = 77), n (%) . | Pemetrexed/carboplatin + placebo (n = 78), n (%) . | All patients (n = 155), n (%) . |
|---|---|---|---|
| Objective response rate | 21 (27) | 25 (32) | 46 (30) |
| Complete response | 1 (1) | 0 (0) | 1 (1) |
| Partial response | 20 (26) | 25 (32) | 45 (29) |
| Stable disease | 31 (40) | 38 (49) | 69 (45) |
| ≥6 months | 9 (12) | 6 (8) | 15 (10) |
| <6 months | 22 (29) | 32 (41) | 54 (35) |
| Progressive disease | 10 (13) | 6 (8) | 16 (10) |
| Not evaluable | 15 (20) | 9 (12) | 24 (16) |
| Response . | Pemetrexed/carboplatin + apatorsen (n = 77), n (%) . | Pemetrexed/carboplatin + placebo (n = 78), n (%) . | All patients (n = 155), n (%) . |
|---|---|---|---|
| Objective response rate | 21 (27) | 25 (32) | 46 (30) |
| Complete response | 1 (1) | 0 (0) | 1 (1) |
| Partial response | 20 (26) | 25 (32) | 45 (29) |
| Stable disease | 31 (40) | 38 (49) | 69 (45) |
| ≥6 months | 9 (12) | 6 (8) | 15 (10) |
| <6 months | 22 (29) | 32 (41) | 54 (35) |
| Progressive disease | 10 (13) | 6 (8) | 16 (10) |
| Not evaluable | 15 (20) | 9 (12) | 24 (16) |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
